API Product   :    Nilotinib HCI Dihydrate*
Nilotinib HCI Dihydrate*
CEP   :    -
WCC   :    ?
Therapeutic Use    :    Tyrosine Kinase Inhibitor(TKI)
Tyrosine Kinase Inhibitor(TKI)
Originator   :    Inhibikase Therapeutics
CAS No.    :    641571-10-0
Trade Name.   :    Tasigna
Molecular Weight   :    529.5245 g/mol
Molecular Formula   :    C28H22F3N7O
Nilotinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Nilotinib is used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (CML) in adults and children who are at least 1 year old.
Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor that is 10–30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells. Nilotinib was developed by Novartis and is sold under the trade name Tasigna.